Immediate hypersensitivity reactions to peanuts are a considerable public health concern due to the acute and severe
IgE mediated reactions. To conduct research on the pathogenesis and
therapeutics of
peanut allergies, it is imperative to have mouse anti-crude peanut extract (CPE)
IgE monoclonal antibodies (mAbs) for both in-vitro and in-vivo assays. Without these tools, it is difficult to advance research in this field. In this study, four hybridomas producing anti-CPE
IgE mAbs were developed and the
IgE mAbs were validated using immune-blot analysis, Sandwich ELISA, Indirect ELISA, a cell-based assay using RBL-2H3 cells, and footpad
type I hypersensitivity reaction studies in mice. The results indicate that two of the four mAbs can be effectively used for both in-vitro and in-vivo
peanut allergy studies, as they induce
allergic reactions with sensitization alone in mice. These novel anti-Ara h1 and
Ara h 3
IgE mAbs, in combination with the detailed protocols outlined in this article, offer valuable guidance for studying acute
allergic reactions involving mast cells across various platforms. With some considerations, the
IgE mAbs can significantly advance
peanut allergy research.